Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.